Fast track — Research LettersAntibody to Haemophilus influenzae type b after routine and catch-up vaccination
References (5)
- et al.
Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity
J Pediatr
(1997) - et al.
An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay
J Immunol Methods
(1990)
Cited by (60)
Laboratory surveillance of invasive Haemophilus influenzae disease in Argentina, 2011–2019
2023, Revista Argentina de MicrobiologiaCitation Excerpt :Infections occurring in children with complete primary Hib vaccination and/or booster dose were unexpected; however, countries such as the United Kingdom, the Netherlands and Gambia have also reported reemergence of invasive infections after full vaccination2,25,32,35. In the UK, an increase in disease rates was observed between 1999 and 2002 in children 0–4 years of age associated mainly with a decline in vaccine-induced immunity in 1–4 year olds31,41. The reasons for vaccine failure were linked to accelerated 3 dose vaccination schedules (at 2, 3 and 4 months of age) since longer intervals are known to be more immunogenic26, lack of a booster dose and use of combined vaccines containing acellular Bordetella pertussis components, which are less immunogenic against Hib27.
Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization
2019, Cell ReportsCitation Excerpt :Unfortunately, following immunization with Hib conjugate and MenC conjugate vaccines in early infancy, antibody levels rapidly wane. By 1 year of age, >25% and >50% of children have antibody levels below the putative threshold of protection for Hib conjugate and MenC organisms, respectively (Trotter et al., 2003; Pace et al., 2015). In the United Kingdom, booster doses of Hib and MenC vaccines were introduced for all children at 1 year of age in 2003 and 2006, respectively (McVernon et al., 2003).
Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003–16): a case-control study
2018, The Lancet Infectious DiseasesCitation Excerpt :Unfortunately, we had insufficient cases to evaluate this in older children or in children who received a subsequent booster dose. A limitation of our study is that, although age at vaccination can affect immune response, we were unable to evaluate this factor, since we did not have enough cases vaccinated at different ages to establish comparisons.7,32 We were also unable to estimate the effectiveness of two primary doses plus a booster dose, since no case had followed that schedule.
Two Decades of Experience With the Haemophilus influenzae Serotype b Conjugate Vaccine in the United Kingdom
2012, Clinical Therapeutics